Raji Shameem, MD, and Timmy Nguyen, MD, discuss clinical trial efficacy data, practical safety considerations, and real-world findings surrounding the use of key frontline regimens for metastatic pancreatic adenocarcinoma: NALIRIFOX, FOLFIRINOX, and gemcitabine plus nab-paclitaxel.
Amer Zeidan, MD, dives into the future of acute myeloid leukemia management for patients who are ineligible for intensive chemotherapy. This section covers the clinical impact of the newly approved all-oral DEC-C plus venetoclax regimen, real-world dose-modification insights, and targeted therapy sequencing.
Explore the shifting treatment paradigms in lower-risk myelodysplastic syndromes. Amer Zeidan, MBBS, MD, Raji Shameem, MD, discuss long-term data from the COMMANDS and MAXILUS trials, the impact of molecular stratification via IPSS-M, and strategic sequencing for patients who are ESA-refractory and RS-negative.
Sikander Ailawadhi, MD, breaks down recent clinical trial data for novel CELMoD combinations, offering practical insights on managing high-grade cytopenias and bridging the gap between community practices and academic centers.
Explore an expert recap of the EHA roundtable featuring Paul G. Richardson, MD, and Muhamed Baljevic, MD, as they debate the transitioning standard of care in relapsed/refractory multiple myeloma. The discussion highlights key phase 3 efficacy data, breaks down the neuro-cognitive and GI tolerability profiles of next-gen molecular glues, and details practical supportive care strategies to overcome community management barriers.
Dr. Husain, MD, discusses how new clinical data from ELCC 2025, including findings from MARIPOSA and FLAURA-2, are redefining first-line treatment and sequencing strategies for EGFR-mutant NSCLC to improve long-term outcomes and CNS control.
An expert explains that real-world data affirm the strong efficacy and manageable safety of bispecific antibodies like teclistamab in relapsed/refractory multiple myeloma—including in patients beyond trial eligibility—and that combining agents such as teclistamab and talquetamab offers promising options for high-risk cases; optimizing safety through step-up dosing, infection prophylaxis, and supportive care enables broader outpatient use, while ongoing research aims to expand their role earlier in treatment and explore stopping strategies after sustained minimal residual disease negativity to personalize and improve long-term patient outcomes.
Sreenivasa Chandana, MD, PhD and Darshil Shah, MD, MPH discuss how different first-line treatment options for metastatic pancreatic adenocarcinoma (including FOLFIRINOX, gemcitabine/nab-paclitaxel, and the newer NALIRIFOX regimen) compare in efficacy and toxicity profiles, emphasizing the importance of patient-specific factors in treatment selection and noting that dose reductions may actually improve survival by allowing patients to remain on therapy longer.
Christopher Lee, MD; Alvaro Martinez, MD; Daniel Kim, MD, MBA; Steven E. Finkelstein, MD; and Dwight E. Heron, MD, MBA, FACRO, FACR, discuss how genomic and genetic research is revolutionizing our understanding of prostate cancer risk, progression, personalized treatment strategies, and potential targeted interventions by identifying specific genetic markers, inherited mutations, and molecular pathways that influence disease development and patient outcomes.
Misako Nagasaka, PhD, MD, discusses an extension of a recent meeting with other expert faculty at the 2024 World Conference on Lung Cancer in San Diego, California, to discuss key updates in HER2-directed therapies across tumor types.
Samer Al-Hadidi, MD, MS, FACP, and Leo Shunyakov, MD, discuss their approaches to dosing talquetamab and treating CNS metastases in patients with relapsed/refractory multiple myeloma, sharing clinical experiences and addressing treatment challenges.
Morie Gertz, MD, and Ajai Chari, MD, discuss evolving treatment paradigms, highlighting VRd as standard frontline therapy for transplant-eligible patients while noting the emerging role of quadruplet regimens (particularly daratumumab-based combinations), strong evidence for antibody-containing regimens in transplant-ineligible patients from trials like MAIA and CEPHEUS, and the promising but logistically complex role of CAR T-cell therapy in early relapsed disease.
Following the 2024 ASCO Annual Meeting, medical oncologists review recent data and discuss the evolving treatment landscape in advanced EGFR-mutant non–small cell lung cancer (NSCLC).
Rafael Fonseca, MD, and Binod Dhakal, MD, analyze recent developments from EHA 2024, including updates on transplant-eligible and ineligible NDMM, the PERSEUS and IsKIA trials, and the impact of CAR T-cell therapy in earlier treatment lines, while offering insights into the evolving treatment landscape and future directions for patient care.
In an extension of a meeting of expert faculty from the ASH 2023 conference, Caitlin Costello, MD, and Matthew Pianko, MD, review key data updates on clinical and real-world evidence in multiple myeloma and share insights on how they can be applied to clinical practice for patients with relapsed/refractory multiple myeloma (RRMM).
A panel of experts on pulmonary and gastrointestinal solid tumors review recent data and discuss the evolving diagnostic and treatment paradigms for patients with NRG1 fusion–positive malignancies.
Educational support for this activity provided by Merus.
Expert oncologists discuss key updates on the treatment of patients with Exon20+ non-small cell lung cancer and consider how they may be applied to clinical practice.
Joselle Cook, M.B.B.S and Matthew James Pianko, MD review the latest updates concerning transplant-ineligible newly diagnosed multiple myeloma (NDMM) and provide insights on the real-world application of clinical data to improve patient outcomes.
Luciano Costa, MD, PhD and Timothy Schmidt, MD discuss key data updates and share pearls for community oncologists concerning transplant-eligible newly diagnosed multiple myeloma (NDMM).
Following updates from the 2022 IKCS meeting, experts in the field of oncology work together to review key clinical data and current treatment strategies in the setting of renal cell carcinoma.
In a new program from CancerNetwork®, experts discuss key data updates in multiple myeloma from ASCO 2022 based on real-world evidence and how they can be applied into clinical practice.